18-membered macrocycles and analogs thereof
View Patent ↗The present invention relates generally to the 18-membered macrocyclic antimicrobial agents called Tiacumicins, specifically, OPT-80 (which is composed almost entirely of the R-Tiacumicin B), pharmaceutical compositions comprising OPT-80, and methods using OPT-80. In particular, this compound is a potent drug for the treatment of bacterial infections, specifically C. difficile infections.
1. A method of treating diarrhea caused by C. difficile gastrointestinal infection in a human patient in need thereof comprising orally administering to said patient a therapeutically effective amount of a compound having the formula (IV):
or a pharmaceutically acceptable salt combined with one or more pharmaceutically acceptable carriers, wherein the compound having formula (IV) is greater than 90% by weight stereomerically pure.
2. The method of claim 1 , wherein the compound of formula (IV) is formulated as a tablet.
3. The method of claim 1 , wherein the compound of formula (IV) is formulated as a capsule.
4. The method of claim 1 , wherein the compound of formula (IV) is greater than 93% by weight stereomerically pure.
5. The method of claim 1 , wherein the compound of formula (IV) is greater than 95% by weight stereomerically pure.
6. The method of claim 1 , wherein the compound of formula (IV) is greater than 97% by weight stereomerically pure.
7. The method of claim 1 , wherein the compound of formula (IV) is substantially free of other diastereomers of the compound.
8. The method of claim 1 , wherein the method consists of administering to the human patient a therapeutically effective amount of the compound having formula (IV) or a pharmaceutically acceptable salt thereof combined with one or more pharmaceutically acceptable carriers.
9. A method of treating diarrhea caused by C. difficile gastrointestinal infection in a human patient in need thereof consisting of orally administering to said patient a therapeutically effective amount of a compound having the formula (IV):
or a pharmaceutically acceptable salt thereof combined with one or more pharmaceutically acceptable carriers, wherein the compound of the formula (IV) is greater than 93% by weight stereomerically pure.
10. The method of claim 9 , wherein the compound of formula (IV) is formulated as a tablet.
11. The method of claim 9 , wherein the compound is formulated as a capsule.
12. The method of claim 9 , wherein the compound of formula (IV) is greater than 95% by weight stereomerically pure.
13. The method of claim 9 , wherein the compound of formula (IV) is greater than 97% by weight stereomerically pure.
14. The method of claim 9 , wherein the compound of formula (IV) is substantially free of other diastereomers of the compound.